Governance of conflicts of interest in postmarketing surveillance research and the canadian drug safety and effectiveness network

Open Medicine

Volumn 4, Issue 2, 2010, Pages

  Ferris, Lorraine E ^a   Lemmens, Trudo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956047001     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Health Canada. Government of Canada works to improve knowledge about the safety and effectiveness of drugs [news release]. 2009 Jan 14. Available: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2009/2009_03-eng.php (accessed 2010 May 15).
2. Vioxx: lessons for Health Canada and the FDA. CMAJ 2005;172(1):5.
3. Dieppe P, Ebrahim S, Martin RM, Jüni P. Lessons from the withdrawal of rofecoxib. BMJ 2004;329:867-868.
4. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709.
5. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006;296:1653-1656.
6. Rossouv JE, Anderson GL, Prentice RL, LaCrox AZ, Koopergerg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3);321-333.
7. United States Department of Justice. Eli Lilly and Company agrees to pay $1.415 billion to resolve allegations of off-label promotion of Zyprexa [news release]. 2009 Jan 15. Available: http://www.justice.gov/civil/ocl/cases/Cases/Eli_Lilly/Lilly%20Press%20Release%20Final%2009-civ-038.pdf (accessed 2010 May 15).
8. Evans D. Pfizer broke the law by promoting drugs for unapproved uses. Bloomberg.com. 2009 Nov 9. Available: http://www.bloomberg.com/apps/news?pid=20601109&sid=a4yV1nYxCGoA (accessed 2010 May 19).
9. United States Department of Health and Human Services. Justice department announces largest health care fraud settlement in its history: Pfizer to pay $2.3 billion for fraudulent marketing [news release]. 2009 Sep 2. Available: http://www.hhs.gov/news/press/2009pres/09/20090902a.html (accessed 2010 May 19).
10. Health Canada. Drugs and Health Products. Authority to require post-market studies [discussion paper]. 2007 Apr 4. Available: http://26448.vws.magma.ca/dhp-mps/homologation-licensing/docs/pma-aac/pma-aac04-eng.php (accessed 2010 May 19).
11. Food and Drug Administration Amendments Act of 2007, Public Law 110-85, Statutes at Law 121 (September 27, 2007), 823-978
12. Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Baciu A, Stratton K, Burke SP, editors. Washington, DC: National Academies Press; 2006. Chapter 5, Regulatory authorities for drug safety; p. 151-176.
13. Department of Health and Human Services Office of Inspector General. FDA's monitoring of postmarketing study commitments. Publ no OE1-01-04-00390. June 2006. Available: http://oig.hhs.gov/oei/reports/oei-01-04-00390.pdf (accessed 2010 May 19).
14. US Government Accountability Office. New drug ppproval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. A report to the Ranking Member, Committee on Finance, U.S. Senate. Publ no GAO 09-866. Washington (DC): GAO; 2009. Available: http://www.gao.gov/new.items/d09866.pdf (accessed 2010 May 19).
15. Health Canada Drugs and Health Products. The use of post-market commitments [discussion paper]. Available: http://26448.vws.magma.ca/dhp-mps/homologation-licensing/docs/condition/ condition01-eng.php (accessed 2010 May 19).
16. Health Canada Drugs and Health Products. Addressing unfulfilled post-market clinical commitments [discussion paper]. Available: http://26448.vws.magma.ca/dhp-mps/homologation-licensing/docs/condition/condition02-eng.php (accessed 2010 May 19).
17. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance-lack of viligance, lack of trust. JAMA 2004;292(21):2647-2650.
18. Lemmens T. Leopards in the temple: restoring integrity to the commercialized research scene. J Law Med Ethics 2004;32(4):641-657.
19. Ray WA, Stein CM. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 2006;354:192-201.
20. Canadian Institutes of Health Research. Drug Safety and Effectiveness Network implementation progress August 2009; 2009 Sept 1. Available: http://www.cihr-irsc.gc.ca/e/40126.html (accessed 2010 May 19).
21. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 2006;166:1938-1942.
22. Rotthoff KW. Product liability litigation: an issue of Merck and lawsuits over Vioxx. Seton Hall Public Law Research Paper No. 1151271. Available: http://ssrn.com/abstract=1151271 (posted 2008 June 28; revised 2009 Jan 24; accessed 2010 May 19).
23. Ethics policy on CIHR partnerships with the for-profit private sector; 2007 March 19-20; Ottawa. Canadian Institutes of Health Research Workshop.
24. Drug Safety and Effectiveness Network Workshop on Potential Legal and Ethical Risks; 2009 March 6; Toronto. Canadian Institutes of Health Research.
25. Canadian Institutes of Health Research. Bernard Prigent, MD, MBA. 2009 Oct 5. Available: http://www.cihr-irsc.gc.ca/e/40472.html (accessed 2010 May 19).
26. Silversides A. Appointment of Pfizer executive to CIHR stirs controversy. CMAJ 2009;181(11):E256-257.
27. Ghali W, Kendall C, Palepu A. Pharmaceutical industry representation on CIHR's governing council. Open Med 2010;4(1):E26-27.
28. Lewis S. Neoliberalism, conflict of interest, and the governance of health research in Canada. Open Med 2010;4(1):E28-30.
29. Baylis F. An intractable conflict of interest. In: The Mark [online forum]; Toronto; 2009 Dec 2. Available: http://www.themarknews. com/articles/727-an-intractable-conflict-of-interest (accessed 2010 May 19.
30. Canada. Parliament. House of Commons Standing Committee on Health. Evidence of Proceedings, meeting no. 47, November 30, 2009. Available: http://www2.parl.gc.ca/HousePublications/Publication.aspx?DocId=4275165&Language=E&Mode=1&Parl=40&Ses=2.
31. Canada. Parliament. House of Commons Standing Committee on Health. Evidence of Proceedings, meeting no. 49, December 7, 2009. Available: http://www2.parl.gc.ca/HousePublications/Publication.aspx?DocId=4302528&Language=E&Mode=1&Parl=40&Ses=2.